Meningococcal Disease
📧 Sign up to get email alerts when something new happens for Meningococcal Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-04-10Clinical Trial Update: Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population [Phase 4]
Phase 4 clinical trial evaluating safety and immunogenicity of meningococcal B and ACWY vaccines in at-risk populations.
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults [Phase 4]
Phase 4 pilot trial evaluating two schedules of the 4CMenB meningococcal vaccine in adolescents and young adults has completed.
-
CLINICAL_TRIALS trial_result · 2019-01-24Clinical Trial Update: Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine [Phase 3]
Phase 3 trial evaluating co-administration of the meningococcal vaccine GSK134612 with Infanrix Hexa versus administering each vaccine separ…
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 [Phase 3]
Phase 3 trial update on antibody persistence and safety/tolerability of a booster dose for the meningococcal B vaccine after completion of t…
-
CLINICAL_TRIALS trial_result · 2018-10-29Clinical Trial Update: Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis. [Phase 1]
Phase 1 safety and immunogenicity study of a serogroup B meningococcal vaccine to prevent meningitis completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-10-22Clinical Trial Update: Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese [Phase 3]
Phase 3 clinical trial update on the immunogenicity and safety of a bivalent meningococcal A and C tetanus toxoid conjugate vaccine in China…
-
CLINICAL_TRIALS trial_result · 2018-09-21Clinical Trial Update: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea [Phase 4]
Phase 4 clinical trial update assessing safety of a single dose of meningococcal ACWY conjugate vaccine across a broad age range in South Ko…
-
CLINICAL_TRIALS trial_result · 2018-09-17Clinical Trial Update: Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m [Phase 3]
Phase 3 trial update of Tritanrix-HepB/Hib-MenAC and Mencevax ACWY vaccines with completed status and results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-06-26Clinical Trial Update: Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents [Phase 2]
Phase 2 trial assessing effectiveness, immunogenicity, and safety of the Meningococcal ABCWY vaccine in healthy adolescents has completed wi…
-
CLINICAL_TRIALS trial_result · 2018-06-15Clinical Trial Update: Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. [Phase 3]
Phase 3 trial assessing safety and immunogenicity of GSK's meningococcal B recombinant vaccine given with routine vaccines to healthy infant…
-
CLINICAL_TRIALS trial_result · 2018-06-04Clinical Trial Update: Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612 [Phase 2]
A Phase 2 study in children assessing non-inferiority and antibody persistence up to five years for GSK's meningococcal vaccine 134612; resu…
-
CLINICAL_TRIALS trial_result · 2018-06-04Clinical Trial Update: Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine [Phase 2]
This clinical trial update reports results from a Phase 2 study evaluating non-inferiority and 5-year persistence of GlaxoSmithKline's MenAC…
-
CLINICAL_TRIALS trial_result · 2018-05-09Clinical Trial Update: Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration [Phase 3]
Phase 3 trial evaluating co-administration of GSK134612 meningococcal vaccine with GSK1024850A pneumococcal vaccine versus separate administ…
-
CLINICAL_TRIALS trial_result · 2018-05-02Clinical Trial Update: Evaluation of Vaccinal and Natural Immunity Against Meningococcus C [NA]
A completed clinical trial evaluated immune responses from vaccination and natural infection against meningococcal serogroup C infections.
-
CLINICAL_TRIALS trial_result · 2018-03-22Clinical Trial Update: Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh. [Phase 2, Phase 3]
Clinical trial update for a locally manufactured meningococcal ACWY vaccine (Ingovax ACWY) in Bangladesh; Phase 2 and Phase 3 non-inferiorit…
-
CLINICAL_TRIALS trial_result · 2017-12-06Clinical Trial Update: Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents [Phase 2]
Phase 2 trial assessing the effectiveness, immunogenicity and safety of the Meningococcal ABCWY vaccine in healthy adolescents; study comple…
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects [Phase 4]
Phase 4 trial update evaluating immunogenicity and safety of a two-dose Menactra series in healthy Japanese adults. The study has completed …
-
CLINICAL_TRIALS trial_result · 2017-10-18Clinical Trial Update: Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects [Phase 3]
Phase 3 trial update comparing GSK134612 in subjects at increased risk for meningococcal disease versus healthy subjects; results have been …
-
CLINICAL_TRIALS trial_result · 2017-10-06Clinical Trial Update: Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects [Phase 3]
Phase 3 non-inferiority trial comparing a meningococcal vaccine GSK134612 to Mencevax in children aged 2-10; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-07-25Clinical Trial Update: Persistence of Antibody Response to N. Meningitidis Group C in Children [Phase 4]
Phase 4 study update shows persistence of antibody responses against Neisseria meningitidis group C in children following vaccination.
-
CLINICAL_TRIALS trial_result · 2017-06-08Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults [Phase 2]
Phase 2 trial comparing GSK 134612 with Menactra in healthy adolescents and adults to evaluate immunogenicity and safety; results were poste…
-
CLINICAL_TRIALS trial_result · 2017-05-02Clinical Trial Update: Testing the Use of Prompts to Increase Adolescent Immunization Rates [NA]
A UCLA-led completed trial tested whether prompts can increase adolescent vaccination uptake for vaccines including meningococcal disease, H…
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years. [Phase 2]
A Phase 2 study comparing vaccine GSK134612 with Menactra in healthy adolescents and young adults (10-25 years) assessed immunogenicity and …
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 [Phase 3]
A Phase 3 trial evaluating the persistence of antibodies after vaccination with the meningococcal vaccine GSK 134612 has completed, with res…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. [Phase 2]
Phase 2 feasibility study of GSK's GSK2202083A vaccine in healthy infants at 3, 5, and 11 months was terminated, with results posted in 2017…